NICE guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care. Find out more about guidance.
- Guidance products
- Published guidance
- New guidance (last 6 months)
- Updated guidance (last 6 months)
Guidance by programme
-
NICE guidelines
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Guidance being developed or updated
Quality standards
Quality standards set out the priority areas for quality improvement in health and social care. Find out more about quality standards.
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance. Find out more about advice.
- Advice products
- Published advice
- New advice (last 6 months)
- Updated advice (last 6 months)
Advice by programme
-
Evidence summaries
Review the best available evidence for selected medicines.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
15 Products
In development (1) | Proposed (1)
There are 2
new
and 0
updated
products since
February 2018
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE guidelines
Review the evidence across broad health and social care topics.
Quality standards
Set out priority areas for quality improvement in health and social care.
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
-
Tocilizumab for treating giant cell arteritis (TA518)
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
-
Deep brain stimulation for intractable trigeminal autonomic cephalalgias (IPG381)
-
Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache (IPG527)
-
Occipital nerve stimulation for intractable chronic migraine (IPG452)
-
Percutaneous closure of patent foramen ovale for recurrent migraine (IPG370)
-
Transcranial magnetic stimulation for treating and preventing migraine (IPG477)
-
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG559)
-
Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)
Evidence summaries
Review the best available evidence for selected medicines.
In development
Proposed
New guidance and advice
Guidance and advice added since February 2018